Biomarker-guided treatment-and-stop-strategy for short acting IL-1 blockade in patients with systemic Juvenile Idiopathic Arthritis. Biomarker-guided treatment-and-stop-strategy for short acting IL-1 blockade in patients with systemi ...
Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis. - ESTIS trial: Early Stop of targeted Treatment in children with Systemic JIA Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in p ...